Replies to post #31432 on NorthWest Biotherapeutics Inc (NWBO)

[koman]

Promising data. An unusual thing though is the lack of PFS data from this trial. I wonder why because that is the usual metrics to look at for rGBM. Maybe more color can be added this thursday. Their conclusion is a stretch w/o actual ctrls being used. PFS and ORR could have shown some complete responses like some other trials have shown for rGBM. What is it with NWBO to do things different from other companies in the GBM field- looking at PFS for a pIII in ndGBM and then looking at OS data for rGBM when others are doing the opposite.

[austinmediainc]

The PR only says he will be discussing the information arm, nothing else in the 15 minutes he is presenting. Was the abstract tied to this conference?

During his presentation, Dr. Bosch will discuss data relating to 51 patients with Glioblastoma multiforme (GBM) brain cancer who were treated with DCVax-L on a compassionate basis in an "Information Arm" outside of the Company's Phase III clinical trial. These patients were not eligible for the clinical trial because they were already showing some actual or apparent re-growth of their brain tumor in imaging at a Baseline Visit when they finished 6 weeks of daily radiotherapy and chemotherapy following the surgical removal of their original tumor as part of the standard of care. Such patients are considered either "rapid progressors" or "pseudo-progressors," based upon whether the appearance of early tumor re-growth can be subsequently confirmed. Dr. Bosch will discuss survival data relating to such patients.